Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Консервативная терапия ожирения: возможности и достижения
Консервативная терапия ожирения: возможности и достижения
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Статистика свидетельствует, что 20–25% населения планеты страдает ожирением, а 30–50% имеет избыточную массу тела. Для того чтобы снизить вероятность развития сердечно-сосудистой патологии или ее осложнений, достаточно снизить массу тела всего на 5–10% от исходной величины. Высокой эффективностью в отношении снижения массы тела обладают средства, ограничивающие всасывание пищевого жира. В клинических исследованиях было показано, что запатентованный комплекс из натуральных волокон (литрамин IQP G-002AS), полученный из опунции индийской (Opuntia ficus-indica) и стандартизованный в отношении липофильной активности, понижает всасывание жира, который содержится в пище, посредством связывания жиров в желудочно-кишечном тракте, что эффективно стимулирует снижение массы тела.
Ключевые слова: избыточная масса тела, ожирение, понижение усвоения жиров, снижение массы тела.
Key words: overweight , obesity , reduced fat digestion , weight loss.
Ключевые слова: избыточная масса тела, ожирение, понижение усвоения жиров, снижение массы тела.
________________________________________________
Key words: overweight , obesity , reduced fat digestion , weight loss.
Полный текст
Список литературы
1. Stevens G, Mascarenhas M, Mathers C. Global health risks: progress and challenges. Bull World Health Organ 2009; 87: 646.
2. Мкртумян А.М. Актуальные проблемы консервативного лечения ожирения. Мед. совет. 2010; 7–8: 21–7.
3. Bjorntorp P. Obesity. Lancet 1997; 350: 423–6.
4. Tounian P, Aggoun Y, Dubern B et al. Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study. Lancet 2001; 385: 1400–04.
5. Ожирение. Под ред. И.И.Дедова, Г.А.Мельниченко. М.: Медицинское информационное агентство, 2004.
6. Rahmouni K, Correia MLG, Haynes WG et al. Obesity-associated hypertension. Hypertension 2005; 45: 9–14.
7. Aronne LJ. Therapeutic options for modifying cardiometabolic risk factors. Am J Med 2007; 120 (3 Suppl. 1): S26–34.
8. Aronne LJ, Segal RK. Adiposity and fat distribution outcome measures: assessment and clinical implications. Obes Res 2002; 10 (1): 14S–21S.
9. Cani P, Amar J, Iglesias M et al. Diabetes 2007; 56: 1761–72.
10. Cani PD, Bibiloni R, Knauf C et al. Diabetes 2008; 57: 1470–81.
11. Turnbaugh P, Ridaura V, Faith J et al. Science Translational Medicine 2009; 1: 6–14.
12. Finer N. Does pharmacologically induced weight loss improve cardiovascular outcome? Impact of anti-obesity agents on cardiovascular risk factors. Eur Heart J 2005; 7 (Suppl._L): L32–8.
13. Collazo-Clavell ML. Safe and effective management of the obese patient. Mayo Clin Proc 1999; 74: 1255–9; quiz 1259.
14. Johansson K, Neovius K, DeSantis SM et al. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obes Rev 2009; 10: 564–75.
15. US Food and Drug Administration. Safety orlistat (marketed as Alli and Xenical): early communication about an ongoing safety review, 2009; p. 180057.
16. Bachmann C. Ein Fasernkomplex zur Gewichts-reduktion und -kontrolle. Ars Medici thema Phytotherapie 2010: 25–7.
17. Cuellar GEM, Ruiz AM, Monsalve MCR et al. Six-month treatment of obesity with sibutramine 15 mg: a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. Obes Res 2000; 8: 71–82.
18. Davidson MH, Hauptman J, DiGirolamo M et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235–42.
19. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106: 473–81.
2. Мкртумян А.М. Актуальные проблемы консервативного лечения ожирения. Мед. совет. 2010; 7–8: 21–7.
3. Bjorntorp P. Obesity. Lancet 1997; 350: 423–6.
4. Tounian P, Aggoun Y, Dubern B et al. Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study. Lancet 2001; 385: 1400–04.
5. Ожирение. Под ред. И.И.Дедова, Г.А.Мельниченко. М.: Медицинское информационное агентство, 2004.
6. Rahmouni K, Correia MLG, Haynes WG et al. Obesity-associated hypertension. Hypertension 2005; 45: 9–14.
7. Aronne LJ. Therapeutic options for modifying cardiometabolic risk factors. Am J Med 2007; 120 (3 Suppl. 1): S26–34.
8. Aronne LJ, Segal RK. Adiposity and fat distribution outcome measures: assessment and clinical implications. Obes Res 2002; 10 (1): 14S–21S.
9. Cani P, Amar J, Iglesias M et al. Diabetes 2007; 56: 1761–72.
10. Cani PD, Bibiloni R, Knauf C et al. Diabetes 2008; 57: 1470–81.
11. Turnbaugh P, Ridaura V, Faith J et al. Science Translational Medicine 2009; 1: 6–14.
12. Finer N. Does pharmacologically induced weight loss improve cardiovascular outcome? Impact of anti-obesity agents on cardiovascular risk factors. Eur Heart J 2005; 7 (Suppl._L): L32–8.
13. Collazo-Clavell ML. Safe and effective management of the obese patient. Mayo Clin Proc 1999; 74: 1255–9; quiz 1259.
14. Johansson K, Neovius K, DeSantis SM et al. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obes Rev 2009; 10: 564–75.
15. US Food and Drug Administration. Safety orlistat (marketed as Alli and Xenical): early communication about an ongoing safety review, 2009; p. 180057.
16. Bachmann C. Ein Fasernkomplex zur Gewichts-reduktion und -kontrolle. Ars Medici thema Phytotherapie 2010: 25–7.
17. Cuellar GEM, Ruiz AM, Monsalve MCR et al. Six-month treatment of obesity with sibutramine 15 mg: a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. Obes Res 2000; 8: 71–82.
18. Davidson MH, Hauptman J, DiGirolamo M et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235–42.
19. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106: 473–81.
2. Мкртумян А.М. Актуальные проблемы консервативного лечения ожирения. Мед. совет. 2010; 7–8: 21–7.
3. Bjorntorp P. Obesity. Lancet 1997; 350: 423–6.
4. Tounian P, Aggoun Y, Dubern B et al. Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study. Lancet 2001; 385: 1400–04.
5. Ожирение. Под ред. И.И.Дедова, Г.А.Мельниченко. М.: Медицинское информационное агентство, 2004.
6. Rahmouni K, Correia MLG, Haynes WG et al. Obesity-associated hypertension. Hypertension 2005; 45: 9–14.
7. Aronne LJ. Therapeutic options for modifying cardiometabolic risk factors. Am J Med 2007; 120 (3 Suppl. 1): S26–34.
8. Aronne LJ, Segal RK. Adiposity and fat distribution outcome measures: assessment and clinical implications. Obes Res 2002; 10 (1): 14S–21S.
9. Cani P, Amar J, Iglesias M et al. Diabetes 2007; 56: 1761–72.
10. Cani PD, Bibiloni R, Knauf C et al. Diabetes 2008; 57: 1470–81.
11. Turnbaugh P, Ridaura V, Faith J et al. Science Translational Medicine 2009; 1: 6–14.
12. Finer N. Does pharmacologically induced weight loss improve cardiovascular outcome? Impact of anti-obesity agents on cardiovascular risk factors. Eur Heart J 2005; 7 (Suppl._L): L32–8.
13. Collazo-Clavell ML. Safe and effective management of the obese patient. Mayo Clin Proc 1999; 74: 1255–9; quiz 1259.
14. Johansson K, Neovius K, DeSantis SM et al. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obes Rev 2009; 10: 564–75.
15. US Food and Drug Administration. Safety orlistat (marketed as Alli and Xenical): early communication about an ongoing safety review, 2009; p. 180057.
16. Bachmann C. Ein Fasernkomplex zur Gewichts-reduktion und -kontrolle. Ars Medici thema Phytotherapie 2010: 25–7.
17. Cuellar GEM, Ruiz AM, Monsalve MCR et al. Six-month treatment of obesity with sibutramine 15 mg: a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. Obes Res 2000; 8: 71–82.
18. Davidson MH, Hauptman J, DiGirolamo M et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235–42.
19. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106: 473–81.
________________________________________________
2. Мкртумян А.М. Актуальные проблемы консервативного лечения ожирения. Мед. совет. 2010; 7–8: 21–7.
3. Bjorntorp P. Obesity. Lancet 1997; 350: 423–6.
4. Tounian P, Aggoun Y, Dubern B et al. Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study. Lancet 2001; 385: 1400–04.
5. Ожирение. Под ред. И.И.Дедова, Г.А.Мельниченко. М.: Медицинское информационное агентство, 2004.
6. Rahmouni K, Correia MLG, Haynes WG et al. Obesity-associated hypertension. Hypertension 2005; 45: 9–14.
7. Aronne LJ. Therapeutic options for modifying cardiometabolic risk factors. Am J Med 2007; 120 (3 Suppl. 1): S26–34.
8. Aronne LJ, Segal RK. Adiposity and fat distribution outcome measures: assessment and clinical implications. Obes Res 2002; 10 (1): 14S–21S.
9. Cani P, Amar J, Iglesias M et al. Diabetes 2007; 56: 1761–72.
10. Cani PD, Bibiloni R, Knauf C et al. Diabetes 2008; 57: 1470–81.
11. Turnbaugh P, Ridaura V, Faith J et al. Science Translational Medicine 2009; 1: 6–14.
12. Finer N. Does pharmacologically induced weight loss improve cardiovascular outcome? Impact of anti-obesity agents on cardiovascular risk factors. Eur Heart J 2005; 7 (Suppl._L): L32–8.
13. Collazo-Clavell ML. Safe and effective management of the obese patient. Mayo Clin Proc 1999; 74: 1255–9; quiz 1259.
14. Johansson K, Neovius K, DeSantis SM et al. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obes Rev 2009; 10: 564–75.
15. US Food and Drug Administration. Safety orlistat (marketed as Alli and Xenical): early communication about an ongoing safety review, 2009; p. 180057.
16. Bachmann C. Ein Fasernkomplex zur Gewichts-reduktion und -kontrolle. Ars Medici thema Phytotherapie 2010: 25–7.
17. Cuellar GEM, Ruiz AM, Monsalve MCR et al. Six-month treatment of obesity with sibutramine 15 mg: a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. Obes Res 2000; 8: 71–82.
18. Davidson MH, Hauptman J, DiGirolamo M et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235–42.
19. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106: 473–81.
Авторы
А.М.Мкртумян
ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России
ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России
________________________________________________
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.